United Therapeutics Corporation
UTHR
$300.60
-$1.81-0.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.53% | 7.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.53% | 7.95% | |||
| Cost of Revenue | -5.30% | 21.87% | |||
| Gross Profit | 1.30% | 6.35% | |||
| SG&A Expenses | 24.93% | 3.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.47% | 10.05% | |||
| Operating Income | -4.78% | 5.78% | |||
| Income Before Tax | -3.57% | 6.81% | |||
| Income Tax Expenses | -2.37% | 6.41% | |||
| Earnings from Continuing Operations | -3.94% | 6.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.94% | 6.94% | |||
| EBIT | -4.78% | 5.78% | |||
| EBITDA | -4.22% | 5.50% | |||
| EPS Basic | -4.37% | 6.46% | |||
| Normalized Basic EPS | -4.25% | 6.03% | |||
| EPS Diluted | -3.32% | 7.20% | |||
| Normalized Diluted EPS | -3.23% | 6.73% | |||
| Average Basic Shares Outstanding | 0.45% | 0.45% | |||
| Average Diluted Shares Outstanding | -0.62% | -0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||